CAMK2G and heart failure: This notion is supported by results from experiments in a mouse model of pressure overload-induced heart failure and in ventricular cardiomyocytes of patients with end-stage HFrEF, where empagliflozin significantly reduced CaMKII activity, which was associated with improved cellular Ca handling as well as acute reduction in [Na]i.